Christopher D Chien
Overview
Explore the profile of Christopher D Chien including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Song H, Benzaoui M, Dwivedi A, Underwood S, Shao L, Achar S, et al.
Mol Ther Methods Clin Dev
. 2024 Feb;
32(1):101171.
PMID: 38298420
Chimeric antigen receptor T cells (CART) have demonstrated curative potential for hematological malignancies, but the optimal manufacturing has not yet been determined and may differ across products. The first step,...
2.
Niswander L, Graff Z, Chien C, Chukinas J, Meadows C, Leach L, et al.
Haematologica
. 2022 Aug;
108(2):457-471.
PMID: 35950535
Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen...
3.
Shalabi H, Qin H, Su A, Yates B, Wolters P, Steinberg S, et al.
Blood
. 2022 May;
140(5):451-463.
PMID: 35605184
Remission durability following single-antigen targeted chimeric antigen receptor (CAR) T-cells is limited by antigen modulation, which may be overcome with combinatorial targeting. Building upon our experiences targeting CD19 and CD22...
4.
Qin H, Yang L, Chukinas J, Shah N, Tarun S, Pouzolles M, et al.
J Immunother Cancer
. 2021 Sep;
9(9).
PMID: 34531250
Background: Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and...
5.
Ishii K, Pouzolles M, Chien C, Erwin-Cohen R, Kohler M, Qin H, et al.
J Clin Invest
. 2020 Sep;
130(10):5425-5443.
PMID: 32925169
Late-onset inflammatory toxicities resembling hemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) occur after chimeric antigen receptor T cell (CAR T cell) infusion and represent a therapeutic challenge. Given the...
6.
Yang Y, Kohler M, Chien C, Sauter C, Jacoby E, Yan C, et al.
Sci Transl Med
. 2017 Nov;
9(417).
PMID: 29167392
Chimeric antigen receptor (CAR)-expressing T cells induce durable remissions in patients with relapsed/refractory B cell malignancies. CARs are synthetic constructs that, when introduced into mature T cells, confer a second,...
7.
Giles A, Chien C, Reid C, Fry T, Park D, Kaplan R, et al.
Pharmacol Ther
. 2016 Sep;
168:53-60.
PMID: 27595927
Hematopoietic cells are increasingly recognized as playing key roles in tumor growth and metastatic progression. Although many studies have focused on the functional interaction of hematopoietic cells with tumor cells,...
8.
Jacoby E, Nguyen S, Fountaine T, Welp K, Gryder B, Qin H, et al.
Nat Commun
. 2016 Jul;
7:12320.
PMID: 27460500
Adoptive immunotherapy using chimeric antigen receptor (CAR) expressing T cells targeting the CD19 B lineage receptor has demonstrated marked success in relapsed pre-B-cell acute lymphoblastic leukaemia (ALL). Persisting CAR-T cells...
9.
Jacoby E, Yang Y, Qin H, Chien C, Kochenderfer J, Fry T
Blood
. 2015 Dec;
127(10):1361-70.
PMID: 26660684
Acute lymphoblastic leukemia (ALL) persisting or relapsing following bone marrow transplantation (BMT) has a dismal prognosis. Success with chimeric antigen receptor (CAR) T cells offers an opportunity to treat these...
10.
Capitini C, Nasholm N, Chien C, Larabee S, Qin H, Song Y, et al.
Blood
. 2014 Aug;
124(12):1976-86.
PMID: 25079358
Selective targeting of non-T cells, including antigen-presenting cells (APCs), is a potential strategy to prevent graft-versus-host-disease (GVHD) but to maintain graft-versus-tumor (GVT) effects. Because type I and II interferons signal...